Odatroltide Shows Promise in Extending Stroke Treatment Window

Lumosa Therapeutics reported encouraging phase 2b data for its investigational stroke therapy LT3001 (odatroltide), adding momentum to a drug designed to both restore blood flow and limit reperfusion injury in acute ischemic stroke. The…